“To assist this process and to support the Reference Committee’s tight schedule, Medicines Australia has collaborated with members and stakeholders to develop a first draft set of recommended terms of reference for the HTA Reform," said CEO Liz de Somer.
Medicines Australia issues 'conversation starter' for HTA review
June 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News
